Sam Brusco, Associate Editor02.24.21
Terumo Corporation signed an agreement to acquire Health Outcomes Sciences (HOS), which HOS specializes in predictive analytics and clinical decision support, enabling personalized, predictive insights at the point of care.
"The acquisition of Health Outcomes Sciences and the ePRISM platform expands Terumo's presence in the digital healthcare arena and represents a compelling growth opportunity for our company,” Terumo Corp. Cardiac and Vascular Company president told the press. “It further allows Terumo to deliver innovative digital solutions, providing healthcare systems with critical data needed to lower the cost of healthcare delivery while substantially improving patient outcomes.”
Instead of relying on broader, generalized population data, ePRISM delivers each patient's unique risks to physicians before treatment. By calculating and assembling a patient's actual procedural risk—which includes unique disease severity, co-morbidities, and demographics—ePRISM provides valuable data to tailor treatment intensity to patients' unique risks. Using validated predictive models in routine care can improve consistency, outcomes and cost-effectiveness across many cardiac procedures and care pathways.
"When combined with Terumo's 100-year history and commitment to transforming global healthcare, our ePRISM technology will enable healthcare providers to deliver uniquely focused patient care; improving patient satisfaction, decreasing variability, optimizing outcomes and minimizing costs. This acquisition provides Terumo with a digital solutions platform that can be scaled globally across multiple healthcare segments," said John Spertus, MD, MPH, FACC, FAHA and Founder of Health Outcomes Sciences.
The acquisition is expected to close at the end of this month. Following, the ePRISM platform will be integrated into Terumo Business Edge, a business unit of Terumo Medical Corp. business unit that provides healthcare systems with tools to reduce care variation, improve quality metrics, minimize cost, and maximize revenue.
"The acquisition of Health Outcomes Sciences and the ePRISM platform expands Terumo's presence in the digital healthcare arena and represents a compelling growth opportunity for our company,” Terumo Corp. Cardiac and Vascular Company president told the press. “It further allows Terumo to deliver innovative digital solutions, providing healthcare systems with critical data needed to lower the cost of healthcare delivery while substantially improving patient outcomes.”
Instead of relying on broader, generalized population data, ePRISM delivers each patient's unique risks to physicians before treatment. By calculating and assembling a patient's actual procedural risk—which includes unique disease severity, co-morbidities, and demographics—ePRISM provides valuable data to tailor treatment intensity to patients' unique risks. Using validated predictive models in routine care can improve consistency, outcomes and cost-effectiveness across many cardiac procedures and care pathways.
"When combined with Terumo's 100-year history and commitment to transforming global healthcare, our ePRISM technology will enable healthcare providers to deliver uniquely focused patient care; improving patient satisfaction, decreasing variability, optimizing outcomes and minimizing costs. This acquisition provides Terumo with a digital solutions platform that can be scaled globally across multiple healthcare segments," said John Spertus, MD, MPH, FACC, FAHA and Founder of Health Outcomes Sciences.
The acquisition is expected to close at the end of this month. Following, the ePRISM platform will be integrated into Terumo Business Edge, a business unit of Terumo Medical Corp. business unit that provides healthcare systems with tools to reduce care variation, improve quality metrics, minimize cost, and maximize revenue.
